Duke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC.
Duke University Medical Center, Durham, NC.
Am Heart J. 2018 May;199:97-104. doi: 10.1016/j.ahj.2018.02.004. Epub 2018 Feb 11.
Despite more than 200 years of clinical experience and a pivotal trial, recently published research has called into question the safety and efficacy of digoxin therapy in heart failure (HF).
HF-ACTION (ClinicalTrials.gov Number: NCT00047437) enrolled 2331 outpatients with HF and an EF ≤35% between April 2003 and February 2007 and randomized them to aerobic exercise training versus usual care. Patients were grouped according to prevalent digoxin status at baseline. The association between digoxin therapy and outcomes was assessed using Cox proportional hazard and inverse-probability weighted (IPW) regression models adjusted for demographics, medical history, medications, laboratory values, quality of life, and exercise parameters.
The prevalence of digoxin therapy decreased from 52% during the first 6 months of enrollment to 35% at the end of the HF-ACTION trial (P <0.0001). Study participants were 59± 13 years of age, 72% were male, and approximately half had an ischemic etiology of HF. Patients receiving digoxin at baseline tended to be younger and were more likely to report New York Heart Association functional class III/IV symptoms (rather than class II) compared to those not receiving digoxin. Patients taking digoxin had worse baseline exercise capacity as measured by peak VO and 6-min walk test and greater impairments in health status as reflected by the Kansas City Cardiomyopathy Questionnaire. The association between digoxin and the risk of death or hospitalization differed depending on whether Cox proportional hazard (Hazard Ratio 1.03, 95% Confidence Interval 0.92-1.16; P = .62) or IPW regression models (HR 1.08, 95% CI 1.00-1.17; P = .057) were used to adjust for potential confounders.
Although digoxin use was associated with high-risk clinical features, the association between digoxin therapy and outcomes was dependent on the statistical methods used for multivariable adjustment. Clinical equipoise exists and additional prospective research is required to clarify the role of digoxin in contemporary clinical practice including its effects on functional capacity, quality of life, and long-term outcomes.
尽管有超过 200 年的临床经验和一项关键试验,但最近发表的研究质疑地高辛治疗心力衰竭(HF)的安全性和疗效。
HF-ACTION(ClinicalTrials.gov 编号:NCT00047437)纳入了 2003 年 4 月至 2007 年 2 月期间 2331 名 EF≤35%的 HF 门诊患者,并将他们随机分为有氧运动训练组与常规护理组。根据基线时地高辛的现有状况将患者分组。使用 Cox 比例风险和逆概率加权(IPW)回归模型评估地高辛治疗与结局之间的关系,调整了人口统计学、病史、药物、实验室值、生活质量和运动参数。
地高辛治疗的患病率从入组前 6 个月的 52%下降到 HF-ACTION 试验结束时的 35%(P<0.0001)。研究参与者的年龄为 59±13 岁,72%为男性,约一半有缺血性 HF 病因。与未服用地高辛的患者相比,基线时服用地高辛的患者年龄较小,更可能报告纽约心脏协会功能 III/IV 级症状(而非 II 级)。服用地高辛的患者在峰值 VO 和 6 分钟步行测试中运动能力较差,在堪萨斯城心肌病问卷中反映的健康状况受损更大。地高辛与死亡或住院风险之间的关系取决于是否使用 Cox 比例风险(风险比 1.03,95%置信区间 0.92-1.16;P=0.62)或 IPW 回归模型(HR 1.08,95%CI 1.00-1.17;P=0.057)来调整潜在混杂因素。
尽管地高辛的使用与高风险的临床特征相关,但地高辛治疗与结局之间的关系取决于用于多变量调整的统计方法。存在临床均衡,需要进一步的前瞻性研究来阐明地高辛在当代临床实践中的作用,包括其对功能能力、生活质量和长期结局的影响。